PharmaMar

EN Texto em inglês Ainda não há artigo no seu idioma: trecho em inglês.

PharmaMar is a Spanish pharmaceutical company headquartered in Colmenar Viejo, Madrid, Spain. Founded in 1986 as a subsidiary of Zeltia, it absorbed its parent company and all its subsidiaries in a reverse merger takeover in 2015. The company is a component of the Madrid Stock Exchange General Index (IGBM) and the IBEX 35 since 2020, after being part of the Ibex Small Cap stock market index. PharmaMar's key ventures include the research and development, manufacturing and marketing of pharmaceutical drugs derived from marine-related resources for the treatment of certain cancers and Alzheimer's disease. Its subsidiary Genomica has also developed molecular testing procedures for infectious diseases including COVID-19. The corporation is also known for genetic analysis and paternity testing in the Spanish market. Its subsidiary Sylentis develops therapies based in gene silencing techniques like RNA interference.